254 related articles for article (PubMed ID: 9076631)
21. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.
Liao YP; Jiang JL; Zou WY; Xu DR; Li J
World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880
[TBL] [Abstract][Full Text] [Related]
22. [The follow-up of serum aminotransferase levels and investigation of hepatitis B virus load in inactive HBsAg carriers].
Olut AI; Ozünlü H; Bozdağ H; Ozkalay N
Mikrobiyol Bul; 2007 Jul; 41(3):429-33. PubMed ID: 17933254
[TBL] [Abstract][Full Text] [Related]
23. [The hepatotoxicity of tuberculosis treatment].
Vidal Pla R; de Gracia X; Gallego B; Algueró C; Bravo C
Med Clin (Barc); 1991 Oct; 97(13):481-5. PubMed ID: 1758204
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: a clinical study.
Ruan P; Xu SY; Zhou BP; Huang J; Gong ZJ
J Int Med Res; 2013 Oct; 41(5):1732-9. PubMed ID: 23908397
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of drug-induced hepatitis occurring in elderly and younger patients during anti-tuberculosis treatment with a regimen including pyrazinamide].
Miyazawa N; Horita N; Tomaru K; Tsukahara T; Takahashi R; Sasaki M; Ishigatsubo Y
Kekkaku; 2013 Mar; 88(3):297-300. PubMed ID: 23672170
[TBL] [Abstract][Full Text] [Related]
26. Differences in risk factors for being either a hepatitis B carrier or anti-hepatitis C+ in a hepatoma-hyperendemic area in rural Taiwan.
Wang CS; Chang TT; Chou P
J Clin Epidemiol; 1998 Sep; 51(9):733-8. PubMed ID: 9731921
[TBL] [Abstract][Full Text] [Related]
27. Role of hepatitis B surface antigen (HBsAg) in identifying true inactive HBsAg carriers infected with genotype C hepatitis B virus.
Yim SY; Um SH; Jung JY; Seo YS; Yim HJ; Ryu HS; Chun HJ; Jeen YT; Kim CD; Keum B; Lee HS
J Clin Gastroenterol; 2014 Feb; 48(2):166-71. PubMed ID: 24045280
[TBL] [Abstract][Full Text] [Related]
28. Assessing risk of liver enzyme elevation in patients with immune-mediated diseases and different hepatitis B virus serostatus receiving anti-TNF agents: a nested case-control study.
Chiu YM; Lai MS; Chan KA
Arthritis Res Ther; 2017 Nov; 19(1):214. PubMed ID: 29089055
[TBL] [Abstract][Full Text] [Related]
29. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.
Durand F; Jebrak G; Pessayre D; Fournier M; Bernuau J
Drug Saf; 1996 Dec; 15(6):394-405. PubMed ID: 8968694
[TBL] [Abstract][Full Text] [Related]
30. Hepatic complications of antituberculous therapy.
Rossouw JE; Saunders SJ
Q J Med; 1975 Jan; 44(173):1-16. PubMed ID: 50605
[TBL] [Abstract][Full Text] [Related]
31. Factors Predicting HBsAg Seroclearance and Alanine Transaminase Elevation in HBeAg-Negative Hepatitis B Virus-Infected Patients with Persistently Normal Liver Function.
Chien TL; Wang JH; Kee KM; Chen CH; Hung CH; Lu SN
PLoS One; 2016; 11(12):e0166543. PubMed ID: 27935953
[TBL] [Abstract][Full Text] [Related]
32. [Study on liver damage caused by anti-TB drug intermittent treatment on patients with HBV-TB co-infection].
Huang LH; Geng WK; Zhang J; Lin DW; Dong F; Zhou LS; Dong YR; Zhang XW
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Mar; 30(3):286-9. PubMed ID: 19642388
[TBL] [Abstract][Full Text] [Related]
33. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
Hadziyannis SJ; Sevastianos V; Rapti I; Vassilopoulos D; Hadziyannis E
Gastroenterology; 2012 Sep; 143(3):629-636.e1. PubMed ID: 22659218
[TBL] [Abstract][Full Text] [Related]
34. Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases.
Baghaei P; Tabarsi P; Chitsaz E; Saleh M; Marjani M; Shemirani S; Pooramiri MV; Kazempour M; Farnia P; Fahimi F; Mansouri D; Masjedi M
Am J Ther; 2010; 17(1):17-22. PubMed ID: 19535968
[TBL] [Abstract][Full Text] [Related]
35. Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up.
Brouwer WP; Chan HL; Brunetto MR; Martinot-Peignoux M; Arends P; Cornberg M; Cherubini B; Thompson AJ; Liaw YF; Marcellin P; Janssen HL; Hansen BE;
Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1481-1489.e5. PubMed ID: 26872398
[TBL] [Abstract][Full Text] [Related]
36. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection.
Chen CH; Hung CH; Hu TH; Wang JH; Lu SN; Su PF; Lee CM
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1984-92.e1. PubMed ID: 26073492
[TBL] [Abstract][Full Text] [Related]
37. Sex difference in chronic hepatitis B virus infection: studies of serum HBeAg and alanine aminotransferase levels in 10,431 asymptomatic Chinese HBsAg carriers.
Chu CM; Sheen IS; Lin SM; Liaw YF
Clin Infect Dis; 1993 May; 16(5):709-13. PubMed ID: 8507764
[TBL] [Abstract][Full Text] [Related]
38. Safety of long-term isoniazid preventive therapy in children with HIV: a comparison of two dosing schedules.
le Roux SM; Cotton MF; Myer L; le Roux DM; Schaaf HS; Lombard CJ; Zar HJ
Int J Tuberc Lung Dis; 2013 Jan; 17(1):26-31. PubMed ID: 23146410
[TBL] [Abstract][Full Text] [Related]
39. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors.
Shakya R; Rao BS; Shrestha B
Ann Pharmacother; 2004 Jun; 38(6):1074-9. PubMed ID: 15122004
[TBL] [Abstract][Full Text] [Related]
40. [Isoniazid-induced hepatic failure. Report of a case].
Pereira RM; Tresoldi AT; Hessel G
Arq Gastroenterol; 2000; 37(1):72-5. PubMed ID: 10962632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
